StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
57
This year
1
Publishing Date
2024 - 03 - 12
1
2023 - 10 - 04
1
2023 - 09 - 26
1
2023 - 09 - 20
1
2023 - 09 - 11
1
2023 - 08 - 30
1
2023 - 08 - 10
1
2023 - 08 - 03
1
2023 - 07 - 05
1
2023 - 06 - 21
1
2023 - 06 - 01
1
2023 - 05 - 24
1
2023 - 05 - 11
1
2023 - 05 - 04
1
2023 - 05 - 03
1
2023 - 04 - 27
1
2023 - 04 - 20
2
2023 - 04 - 19
1
2023 - 04 - 11
1
2023 - 04 - 04
1
2023 - 02 - 09
1
2023 - 01 - 26
1
2023 - 01 - 10
1
2022 - 12 - 05
1
2022 - 11 - 28
1
2022 - 11 - 10
1
2022 - 10 - 24
1
2022 - 10 - 04
1
2022 - 09 - 21
1
2022 - 09 - 19
2
2022 - 09 - 07
1
2022 - 09 - 06
1
2022 - 08 - 22
1
2022 - 08 - 19
1
2022 - 08 - 12
1
2022 - 08 - 09
1
2022 - 07 - 27
1
2022 - 07 - 25
1
2022 - 07 - 12
1
2022 - 07 - 06
1
2022 - 06 - 24
1
2022 - 06 - 07
1
2022 - 06 - 06
1
2022 - 05 - 18
1
2022 - 05 - 12
1
2022 - 05 - 11
1
2022 - 05 - 02
1
2022 - 04 - 28
1
2022 - 04 - 25
1
2022 - 04 - 11
1
2022 - 03 - 01
1
2022 - 02 - 17
1
2022 - 02 - 14
1
2022 - 02 - 09
1
2022 - 02 - 01
1
Sector
Commercial services
1
Health technology
57
Manufacturing
1
Tags
Acquisition
1
Agreement
4
Antiviral
1
Application
2
Asco
1
Authorization
9
Biomidwest
2
Blue
1
Breast
1
Business
1
Cancer
4
Clinical-trials-phase-ii
3
Clinical-trials-phase-iii
4
Collaboration
1
Condom
1
Conference
7
Covid
1
Covid-19
21
Disease
5
Drug
3
Earnings
2
Emergency use authorization
4
Entadfi
2
Events
2
Fda
9
Financial
8
Global
4
Granted
2
Grants
5
Growth
1
Health
3
Her2-
1
Initiated
1
International
1
Market
1
Medical
1
Meeting
4
N/a
37
Nasdaq
4
Obesity
1
People
2
Phase 2b
2
Phase 3
6
Positive
3
Preclinical
2
Presentation
5
Program
3
Prostate cancer
2
Report
7
Research
5
Respiratory
6
Results
12
Review
5
Risk
7
Sabizabulin
22
Study
4
Treatment
8
Trial
5
Update
2
Year
2
Entities
Abbott laboratories
56
Abbvie inc.
111
Abcellera biologics inc
12
Ac immune sa
35
Adc therapeutics sa
13
Agios pharmaceuticals, inc.
10
Akouos, inc.
11
Alnylam pharmaceuticals, inc.
38
Amgen inc.
88
Astellas pharma inc
25
Astrazeneca plc
97
Aveo pharmaceuticals, inc.
25
Baxter international inc.
14
Becton, dickinson and company
21
Beigene, ltd.
19
Biocryst pharmaceuticals, inc.
13
Biogen inc.
20
Biontech se
14
Blueprint medicines corporation
20
Boston scientific corporation
10
Bristol-myers squibb company
106
Clovis oncology, inc.
20
Eli lilly and company
1708
Epizyme, inc.
20
Exelixis, inc.
13
Gilead sciences, inc.
35
Glaxosmithkline plc
106
Hutchison china meditech limited
11
Icon plc
10
Illumina, inc.
15
Incyte corporation
207
Insulet corporation
14
Johnson & johnson
175
Karyopharm therapeutics inc.
20
Ligand pharmaceuticals incorporated
10
Medtronic plc
14
Merus n.v.
21
Nektar therapeutics
10
Novartis ag
138
Novo nordisk a/s
82
Omeros corporation
15
Otonomy, inc.
13
Pfizer, inc.
80
Point biopharma global inc
10
Precision biosciences, inc.
11
Proqr therapeutics n.v.
17
Regeneron pharmaceuticals, inc.
36
Rigel pharmaceuticals, inc.
41
Sanofi
335
Takeda pharmaceutical company limited
42
Terumo corp
14
Teva pharmaceutical industries ltd
61
Thermo fisher scientific inc
14
Ucb s.a.
11
United therapeutics corporation
14
Verastem, inc.
11
Vertex pharmaceuticals incorporated
12
Veru inc.
57
Viatris inc.
18
Y-mabs therapeutics, inc.
18
Symbols
ABBV
2
ABT
2
ADBE
1
ADXS
1
ALPMF
1
ALPMY
1
ALT
1
AMGN
1
ATXI
1
AZN
1
AZNCF
1
BIOL
1
BTCY
1
BVS
1
BWV
2
CURV
2
DAKT
1
ENVX
2
EVFM
1
FBIO
1
FXLV
1
GILD
4
GLAXF
1
GSK
1
IMNM
1
JNJ
2
LLY
57
MEDE
1
MS
2
NEO
2
NVO
1
NVS
1
NVSEF
1
OLPX
1
OPK
1
PFE
1
RBGLY
7
RBGPF
7
SGLY
2
SI
2
SNY
3
SNYNF
2
SWKH
1
TEVJF
3
TWST
2
TXMD
1
VERU
146
VTRS
1
VWE
1
YMAB
1
Exchanges
Nasdaq
57
Nyse
57
Crawled Date
2024 - 03 - 12
1
2023 - 10 - 04
1
2023 - 09 - 26
1
2023 - 09 - 20
1
2023 - 09 - 11
1
2023 - 08 - 30
1
2023 - 08 - 10
1
2023 - 08 - 03
1
2023 - 07 - 05
1
2023 - 06 - 21
1
2023 - 06 - 01
1
2023 - 05 - 24
1
2023 - 05 - 11
1
2023 - 05 - 04
1
2023 - 05 - 03
1
2023 - 04 - 27
1
2023 - 04 - 20
2
2023 - 04 - 19
1
2023 - 04 - 11
1
2023 - 04 - 04
1
2023 - 02 - 09
1
2023 - 01 - 26
1
2023 - 01 - 10
1
2022 - 12 - 05
1
2022 - 11 - 28
1
2022 - 11 - 10
1
2022 - 10 - 24
1
2022 - 10 - 04
1
2022 - 09 - 21
1
2022 - 09 - 19
2
2022 - 09 - 07
1
2022 - 09 - 06
1
2022 - 08 - 22
1
2022 - 08 - 19
1
2022 - 08 - 12
1
2022 - 08 - 09
1
2022 - 07 - 27
1
2022 - 07 - 25
1
2022 - 07 - 12
1
2022 - 07 - 06
1
2022 - 06 - 24
1
2022 - 06 - 07
1
2022 - 06 - 06
1
2022 - 05 - 18
1
2022 - 05 - 12
1
2022 - 05 - 11
1
2022 - 05 - 02
1
2022 - 04 - 28
1
2022 - 04 - 25
1
2022 - 04 - 11
1
2022 - 03 - 01
1
2022 - 02 - 17
1
2022 - 02 - 14
1
2022 - 02 - 09
1
2022 - 02 - 01
1
Crawled Time
02:00
1
11:00
9
12:00
11
12:20
2
12:30
1
13:00
8
13:20
2
13:30
1
14:00
6
14:30
3
15:00
1
15:20
2
17:00
4
18:00
1
21:00
5
Source
www.biospace.com
20
www.globenewswire.com
36
www.prnewswire.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
entities :
Veru inc.
symbols :
LLY
save search
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
Published:
2024-03-12
(Crawled : 12:00)
- globenewswire.com
PFE
A
|
$25.615
0.89%
9.9M
|
Health Technology
|
-10.4%
|
O:
-0.21%
H:
0.11%
C:
-1.06%
LLY
|
$731.1
-1.99%
1M
|
Health Technology
|
2.23%
|
O:
0.9%
H:
2.03%
C:
1.89%
VERU
|
$1.52
7.04%
920K
|
Health Technology
|
115.81%
|
O:
-0.53%
H:
2.22%
C:
-3.59%
ALT
|
$6.775
-1.67%
710K
|
Commercial Services
|
-30.19%
|
O:
0.3%
H:
11.41%
C:
9.8%
medical
program
Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Weight Loss by Preventing Muscle Wasting and Further Increasing Fat Loss in a Phase 2b Obesity Clinical Study
Published:
2023-10-04
(Crawled : 13:00)
- globenewswire.com
NVO
|
$123.43
0.55%
1.4M
|
Health Technology
|
41.87%
|
O:
1.88%
H:
0.59%
C:
-0.44%
LLY
|
$731.1
-1.99%
1M
|
Health Technology
|
39.79%
|
O:
-2.39%
H:
0.0%
C:
0.0%
VERU
|
$1.52
7.04%
920K
|
Health Technology
|
91.58%
|
O:
6.22%
H:
1.26%
C:
-6.19%
ozempic
obesity
study
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)
Published:
2023-09-26
(Crawled : 13:00)
- globenewswire.com
LLY
|
$731.1
-1.99%
1M
|
Health Technology
|
35.94%
|
O:
-0.17%
H:
0.0%
C:
0.0%
VERU
|
$1.52
7.04%
920K
|
Health Technology
|
68.63%
|
O:
5.69%
H:
3.37%
C:
-10.11%
fda
sabizabulin
respiratory
trial
agreement
Veru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 28th, 2023
Published:
2023-09-20
(Crawled : 13:00)
- globenewswire.com
LLY
|
$731.1
-1.99%
1M
|
Health Technology
|
30.58%
|
O:
-0.21%
H:
0.0%
C:
0.0%
VERU
|
$1.52
7.04%
920K
|
Health Technology
|
71.81%
|
O:
1.63%
H:
11.9%
C:
9.23%
conference
global
Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer
Published:
2023-09-11
(Crawled : 11:00)
- globenewswire.com
LLY
|
$731.1
-1.99%
1M
|
Health Technology
|
31.09%
|
O:
2.42%
H:
0.0%
C:
0.0%
VERU
|
$1.52
7.04%
920K
|
Health Technology
|
37.2%
|
O:
1.45%
H:
0.95%
C:
0.0%
breast
cancer
her2-
study
Veru to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th, 2023
Published:
2023-08-30
(Crawled : 12:30)
- globenewswire.com
LLY
|
$731.1
-1.99%
1M
|
Health Technology
|
35.52%
|
O:
0.18%
H:
0.49%
C:
-1.26%
VERU
|
$1.52
7.04%
920K
|
Health Technology
|
32.71%
|
O:
0.0%
H:
2.8%
C:
2.8%
conference
global
Veru Reports Fiscal 2023 Third Quarter Financial Results
Published:
2023-08-10
(Crawled : 11:00)
- globenewswire.com
LLY
|
$731.1
-1.99%
1M
|
Health Technology
|
44.58%
|
O:
0.81%
H:
1.01%
C:
-0.41%
VERU
|
$1.52
7.04%
920K
|
Health Technology
|
31.48%
|
O:
0.93%
H:
1.83%
C:
0.0%
financial
results
Veru to Report Fiscal 2023 Third Quarter Financial Results on August 10, 2023
Published:
2023-08-03
(Crawled : 12:20)
- globenewswire.com
LLY
|
$731.1
-1.99%
1M
|
Health Technology
|
64.47%
|
O:
-1.1%
H:
0.0%
C:
0.0%
VERU
|
$1.52
7.04%
920K
|
Health Technology
|
21.37%
|
O:
-0.85%
H:
3.45%
C:
0.86%
report
financial
results
Prostate Cancer Global Market to Witness Upsurge in Growth at a CAGR of ~5% by 2028 | DelveInsight
Published:
2023-07-05
(Crawled : 21:00)
- prnewswire.com
ALPMY
|
$9.47
520K
|
Manufacturing
|
-34.65%
|
O:
0.86%
H:
0.0%
C:
-1.01%
NVS
|
$93.815
1.35%
410K
|
Health Technology
|
-5.93%
|
O:
-1.17%
H:
0.63%
C:
0.22%
LLY
|
$731.1
-1.99%
1M
|
Health Technology
|
61.21%
|
O:
-0.55%
H:
0.97%
C:
0.02%
VERU
|
$1.52
7.04%
920K
|
Health Technology
|
18.33%
|
O:
-0.83%
H:
0.0%
C:
-6.72%
OPK
|
$1.235
0.41%
400K
|
Health Technology
|
-41.43%
|
O:
-1.19%
H:
1.2%
C:
-0.72%
ADXS
|
$0.57
9.5K
|
Health Technology
|
-40.0%
|
O:
0.0%
H:
0.0%
C:
-6.83%
cancer
global
growth
market
Veru Inc.’s Oncology Drug Research Program Partner, The University of Tennessee Health Science Center, Awarded Two New Federal Grants
Published:
2023-06-21
(Crawled : 12:00)
- globenewswire.com
LLY
|
$731.1
-1.99%
1M
|
Health Technology
|
66.12%
|
O:
0.56%
H:
0.18%
C:
-0.33%
VERU
|
$1.52
7.04%
920K
|
Health Technology
|
16.39%
|
O:
0.82%
H:
0.0%
C:
-1.63%
drug
health
research
program
grants
Veru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory Board
Published:
2023-06-01
(Crawled : 12:00)
- globenewswire.com
LLY
|
$731.1
-1.99%
1M
|
Health Technology
|
74.82%
|
O:
0.19%
H:
1.52%
C:
1.45%
VERU
|
$1.52
7.04%
920K
|
Health Technology
|
43.43%
|
O:
1.01%
H:
3.5%
C:
-2.41%
disease
Veru to Present at the Jefferies Healthcare Conference
Published:
2023-05-24
(Crawled : 12:00)
- globenewswire.com
LLY
|
$731.1
-1.99%
1M
|
Health Technology
|
77.4%
|
O:
0.19%
H:
1.17%
C:
0.42%
VERU
|
$1.52
7.04%
920K
|
Health Technology
|
31.48%
|
O:
-0.93%
H:
1.87%
C:
-0.93%
conference
Veru Reports Fiscal 2023 Second Quarter Financial Results
Published:
2023-05-11
(Crawled : 11:00)
- globenewswire.com
LLY
|
$731.1
-1.99%
1M
|
Health Technology
|
72.23%
|
O:
0.18%
H:
0.03%
C:
-0.26%
VERU
|
$1.52
7.04%
920K
|
Health Technology
|
-4.7%
|
O:
1.34%
H:
0.0%
C:
-18.54%
financial
results
Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS
Published:
2023-05-04
(Crawled : 12:00)
- globenewswire.com
LLY
|
$731.1
-1.99%
1M
|
Health Technology
|
74.12%
|
O:
0.06%
H:
0.29%
C:
-0.7%
VERU
|
$1.52
7.04%
920K
|
Health Technology
|
11.81%
|
O:
0.0%
H:
2.36%
C:
0.0%
covid-19
fda
sabizabulin
treatment
risk
trial
agreement
Veru Enters into Common Stock Purchase Agreement for Up to $100 Million with Lincoln Park Capital
Published:
2023-05-03
(Crawled : 12:00)
- globenewswire.com
LLY
|
$731.1
-1.99%
1M
|
Health Technology
|
85.74%
|
O:
2.68%
H:
4.62%
C:
3.89%
VERU
|
$1.52
7.04%
920K
|
Health Technology
|
12.7%
|
O:
-2.38%
H:
6.93%
C:
3.25%
agreement
Veru to Report Fiscal 2023 Second Quarter Financial Results on May 11, 2023
Published:
2023-04-27
(Crawled : 11:00)
- globenewswire.com
LLY
|
$731.1
-1.99%
1M
|
Health Technology
|
99.53%
|
O:
3.98%
H:
1.86%
C:
-0.23%
VERU
|
$1.52
7.04%
920K
|
Health Technology
|
10.94%
|
O:
3.13%
H:
0.0%
C:
-3.79%
report
financial
results
Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset
Published:
2023-04-20
(Crawled : 12:20)
- biospace.com/
BWV
|
$0.1802
5.44%
530K
|
|
-83.37%
|
O:
1.51%
H:
2.73%
C:
-2.73%
LLY
|
$731.1
-1.99%
1M
|
Health Technology
|
102.65%
|
O:
0.25%
H:
1.26%
C:
0.92%
VERU
|
$1.52
7.04%
920K
|
Health Technology
|
37.86%
|
O:
2.91%
H:
16.04%
C:
13.21%
entadfi
water
acquisition
blue
Veru Sells ENTADFI® Business for $20 Million Plus up to an Additional $80 Million from Sales Milestones
Published:
2023-04-20
(Crawled : 11:00)
- globenewswire.com
BWV
|
$0.1802
5.44%
530K
|
|
-83.37%
|
O:
1.51%
H:
2.73%
C:
-2.73%
LLY
|
$731.1
-1.99%
1M
|
Health Technology
|
102.65%
|
O:
0.25%
H:
1.26%
C:
0.92%
VERU
|
$1.52
7.04%
920K
|
Health Technology
|
37.86%
|
O:
2.91%
H:
16.04%
C:
13.21%
entadfi
sales
business
plus
Veru Enters Into Supply Agreement with Afaxys to Expand Access to FC2 Female Condom® in U.S. Public Health Sector
Published:
2023-04-19
(Crawled : 13:00)
- globenewswire.com
LLY
|
$731.1
-1.99%
1M
|
Health Technology
|
102.96%
|
O:
0.17%
H:
0.2%
C:
-0.02%
VERU
|
$1.52
7.04%
920K
|
Health Technology
|
37.86%
|
O:
-1.94%
H:
4.95%
C:
1.98%
condom
health
agreement
Veru Announces Preclinical Study Results that Demonstrate Sabizabulin Inhibits Poxviruses
Published:
2023-04-11
(Crawled : 14:00)
- biospace.com/
LLY
|
$731.1
-1.99%
1M
|
Health Technology
|
104.57%
|
O:
0.21%
H:
0.28%
C:
-1.01%
VERU
|
$1.52
7.04%
920K
|
Health Technology
|
42.0%
|
O:
0.0%
H:
9.0%
C:
1.0%
sabizabulin
preclinical
results
study
← Previous
1
2
3
Next →
Gainers vs Losers
81%
19%
Top 10 Gainers
AGBA
|
News
|
$1.37
242.5%
76M
|
Finance
EGOX
|
$0.0606
68.33%
250M
|
NVFY
|
$3.45
63.51%
20M
|
Consumer Durables
CHRO
|
$1.73
41.22%
46K
|
n/a
ZCMD
|
$1.98
36.55%
27M
|
Commercial Services
RWOD
|
$10.61
32.68%
5.1M
|
n/a
PAPL
|
$2.07
26.22%
550K
|
AULT
|
$0.304
25.57%
47M
|
Manufacturing
WISA
4
|
$7.19
22.07%
18M
|
Electronic Technology
MCB
4
|
$39.53
19.43%
88K
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.